1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Pfizer’s Talzenna/Xtandi Combo Hits On OS Endpoint In Prostate Cancer

 
• By Jessica Merrill

An overall survival benefit for patients in TALAPRO-2 could pave the way for a broader label for the combination in metastatic prostate cancer.

Pfizer announced positive overall survival data in metastatic prostate cancer • Source: Shutterstock

Positive overall survival (OS) data from the Phase III TALAPRO-2 trial could position Pfizer Inc. Inc.’s Talzenna (talazoparib) and Xtandi (enzalutamide) for broader use in metastatic prostate cancer.

Key Takeaways
  • Pfizer’s PARP inhibitor Talzenna with Xtandi showed an overall survival benefit in patients with metastatic castration resistant prostate cancer regardless of mutation status.
  • Talzenna and Xtandi are the first PARP/ARPI combo to demonstrate improved survival in patients regardless of mutation status, a possible competitive advantage

The company announced on 10 October that the combination of the poly ADP-ribose polymerase (PARP) inhibitor Talzenna with the commonly used androgen receptor pathway inhibitor (ARPI) Xtandi resulted in a statistically significant and clinically meaningful OS improvement in all-comers as well as in those with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.